Back to News
Private Equity

Trivest Tests Market for GetixHealth

By Armie Margaret Lee
|
Published: January 4th, 2023
The firm has retained Guggenheim to shop the revenue cycle management company, The Deal has learned.

Private equity firm Trivest Partners LP has placed its revenue cycle management platform, GetixHealth LLC, on the auction block, The Deal has learned.

Trivest engaged Guggenheim Securities LLC to run an auction for GetixHealth, according to two industry sources. First-round bids were expected to be due by late November, one of the sources said. The seller may still be accepting indications of interest in the early weeks of December, however, a second of the sources suggested.

Sugar Land, Texas-based GetixHealth provides outsourced revenue cycle and medical billing services to physicians, hospitals, university medical centers and other healthcare facilities. The company generates annual Ebitda in the neighborhood of $25 million, the two sources said.

In a majority stake sale, the business could fetch an Ebitda multiple in the low double digits, estimated one of the sources familiar with the auction process and a third industry source familiar with the company.

GetixHealth advertises that it operates in at least 11 states and serves 400 providers and 15,000 physicians. The company also seemingly has some operations in India, based on its website.

Trivest invested in the company in February 2015 through Trivest Fund V, which closed with $415 million in 2012.

GetixHealth has acquired businesses including Qube LLC, SVA Healthcare Services LLC, Insurance Data Services Inc. and Grant & Weber Washington Inc.’s early-out recovery solutions business.

Editor’s note: The original, full version of this article was published Dec. 6, 2022, on The Deal’s premium subscription website. For access, log in to TheDeal.com or use the form below to request a free trial.

This Content is Only for The Deal Subscribers

The Deal provides actionable, intraday coverage of mergers, acquisitions and all other changes in corporate control to institutional investors, private equity, hedge funds and the firms that serve them.

If you’re already a subscriber, log in to view this article here.

More From Private Equity